1Reich K, Pinter A, Lacour JP, et al; IXORA-S Investigators. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014-1023. https://doi.org/10.1111/bjd.15666
2Wasel N, Thaçi D, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S). Dermatol Ther (Heidelb). 2020;10(4):663-670. https://doi.org/10.1007/s13555-020-00383-x
3Paul C, van deKerkhof P, Dutronc Y. 52-Week results from IXORA-S: a randomized head-to-head trial of ixekizumab and ustekinumab in patients with moderate-to-severe plaque psoriasis. Poster presented at: Psoriasis Gene to Clinic, 8th International Congress; November 30-December 2, 2017; London, UK. Br J Dermatol. 2017;177(5):e235-e307. https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.16059
4Data on file, Eli Lilly and Company and/or one of its subsidiaries.
5Burge R, Papadimitropoulos M, Henneges C, et al. Ixekizumab treatment leads to early resolution of bothersome symptoms versus ustekinumab. Poster presented at: ISPOR Latin America Conference; September 15-17, 2017; Sao Paulo, Brazil.
6Wasel N, Dutronc Y, Schinzel B, Lacour JP. Comparison of ixekizumab and ustekinumab efficacy in the treatment of nail lesions of patients with moderate-to-severe plaque psoriasis: 52-week data from the IXORA-S trial. Abstract presented at: 27th Congress of the European Academy of Dermatology and Venereology (EADV); September 12-16, 2018; Paris, France.